B-cell Lymphoma Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Biegene, Oncternal Therapeutics, Inc

The B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“B-cell Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-cell Lymphoma Market.

Some of the key takeaways from the B-cell Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel B-cell Lymphoma treatment therapies with a considerable amount of success over the years. 
• B-cell Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-cell Lymphoma treatment 

• Emerging B-cell Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-cell Lymphoma market in the coming years.   
• In March 2023, Oncternal Therapeutics, Inc. has commenced a trial named “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.” This trial aims to evaluate Zilovertamab, an ROR1 Antibody, in combination with Ibrutinib versus Ibrutinib combined with a placebo in individuals diagnosed with Relapsed or Refractory Mantle Cell Lymphoma.
• In May 2023, Bristol Myers Squibb has reported favorable initial findings from two trials: TRANSCEND FL, a Phase 2 single-arm study, and TRANSCEND NHL 001, a pivotal Phase 1 single-arm study. These studies assessed the efficacy of Breyanzi (lisocabtagene maraleucel) in patients dealing with relapsed or refractory follicular lymphoma (FL) and B-cell non-Hodgkin lymphoma, including mantle cell lymphoma (MCL). The results indicated that both studies met their primary objective of overall response rate. Breyanzi demonstrated statistically significant and clinically meaningful responses in treating relapsed or refractory FL and MCL.
• In May 2023, Janssen Biotech, Inc., a branch of the Janssen Pharmaceutical Companies under Johnson & Johnson, has disclosed its global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG). The agreement aims to jointly develop, manufacture, and market advanced chimeric antigen receptor (CAR) T-cell therapies targeted for treating B-cell malignancies.
• In May 2023, Genmab A/S declared that the U.S. Food and Drug Administration (FDA) has granted approval for EPKINLY™ (epcoritamab-bysp) as the inaugural and sole T-cell engaging bispecific antibody designated for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This includes DLBCL not otherwise specified (NOS), encompassing cases originating from indolent lymphoma, and high-grade B-cell lymphoma, following two or more lines of systemic therapy.
• In January 2023, Fate Therapeutics, Inc. disclosed their decision to reject a proposal from Janssen Biotech, Inc. (“Janssen”) regarding the continuation of their collaboration and option agreement under revised terms and conditions. Consequently, this refusal has led to the termination of the agreement, and all ongoing collaboration activities between the parties are scheduled to be concluded by the first quarter of 2023.

B-cell Lymphoma Overview

B-cell Lymphoma is a cancer originating from B cells, a crucial component of the immune system. This type of lymphoma can manifest as either slow-growing (indolent) or fast-growing (aggressive). Generally, most B-cell lymphomas belong to the category of non-Hodgkin lymphomas. Within this classification, there exist numerous diverse types of B-cell non-Hodgkin lymphomas.

Get a Free Sample PDF Report to know more about B-cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight

Emerging B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

• VIP 924: Vincerx Pharma
• UBX-303-1: Ubix Therapeutics
• BMF-219: Biomea Fusion Inc.
• SHR-A1912: Shanghai Hengrui Pharmaceutical
• Ociperlimab: BeiGene
• AUTO3: Autolus Limited
• GNC-038: SystImmune Inc
• Poseltinib: Hanmi Pharmaceutical
• Abexinostat: Xynomic Pharmaceuticals
• PF-07901801: Pfizer
• Odronextamab: ZAI Lab
• Zilovertamab: Oncternal Therapeutics
• PF-07901801: Pfizer
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.     
• TG-1801: TG Therapeutics, Inc.

B-cell Lymphoma Route of Administration

B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

B-cell Lymphoma Molecule Type

B-cell Lymphoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

B-cell Lymphoma Pipeline Therapeutics Assessment

• B-cell Lymphoma Assessment by Product Type
• B-cell Lymphoma By Stage and Product Type
• B-cell Lymphoma Assessment by Route of Administration
• B-cell Lymphoma By Stage and Route of Administration
• B-cell Lymphoma Assessment by Molecule Type
• B-cell Lymphoma by Stage and Molecule Type

DelveInsight’s B-cell Lymphoma Report covers around 170+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further B-cell Lymphoma product details are provided in the report. Download the B-cell Lymphoma pipeline report to learn more about the emerging B-cell Lymphoma therapies

Some of the key companies in the B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for B-cell Lymphoma are – Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.

B-cell Lymphoma Pipeline Analysis:

The B-cell Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of B-cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Lymphoma Treatment.
• B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about B-cell Lymphoma drugs and therapies

B-cell Lymphoma Pipeline Market Drivers

• Increase in prevalence of B-cell Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-cell Lymphoma Market.

B-cell Lymphoma Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-cell Lymphoma Market growth.

Scope of B-cell Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key B-cell Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others
• Key B-cell Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others
• B-cell Lymphoma Therapeutic Assessment: B-cell Lymphoma current marketed and B-cell Lymphoma emerging therapies
• B-cell Lymphoma Market Dynamics: B-cell Lymphoma market drivers and B-cell Lymphoma market barriers 

Request for Sample PDF Report for B-cell Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. B-cell Lymphoma Report Introduction

2. B-cell Lymphoma Executive Summary

3. B-cell Lymphoma Overview

4. B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. B-cell Lymphoma Pipeline Therapeutics

6. B-cell Lymphoma Late Stage Products (Phase II/III)

7. B-cell Lymphoma Mid Stage Products (Phase II)

8. B-cell Lymphoma Early Stage Products (Phase I)

9. B-cell Lymphoma Preclinical Stage Products

10. B-cell Lymphoma Therapeutics Assessment

11. B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. B-cell Lymphoma Key Companies

14. B-cell Lymphoma Key Products

15. B-cell Lymphoma Unmet Needs

16 . B-cell Lymphoma Market Drivers and Barriers

17. B-cell Lymphoma Future Perspectives and Conclusion

18. B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/